A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.
Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC
Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV
Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy
EMA Validates MAA for Frontline Nivolumab/Ipilimumab for MSI-H/dMMR mCRC
Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC